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Because of its superior sensitivity toward soft tissues, including neoplasm, MRI 
imaging is rapidly becoming one of preferred imaging modality. Improving the 
sensitivity of MRI for the detection of aggressive lymphomas, DLBCL, is vital in the 
diagnostic workup, staging and treatment planning. It is also useful for the better 
understanding of treatment outcomes in the disease follow-up process.  
In this study, the sensitivity of the four MRI sequences, before and after treatment, 
in delineating the lesion and evaluating the response to treatment is studied.  
Eighteen patients with histologically proven DLBCL underwent a 3T MR scanning 
before treatment, and fifteen of them were re-scanned one week after chemotherapy. 
The four MRI sequences studied are pre and post contrast enhanced T1-weighted 
imaging, T2-weighted imaging with and without fat suppression. Before treatment all 
but one patient had not had T2-weighted fat suppression MRI protocol. The four MRI 
sequence were quantitatively evaluated based on the normalized mean signal intensity 
calculated from the measured signal intensities of the lesion and normal tissues. 
The conspicuity level of the tumor was superior on T2-weighted with fat suppression 
images both before and after treatment. And these difference were significant (p<0.05).  
The post contrast enhanced images ranked the second. One week after treatment, there 
were a significant decrease in the signal contrast ratio of the T2-weighted with fat 
suppression images whereas there were no significant decrease in the signal contrast 
ratio of the post contrast enhanced T1-weighted images.  
T2-weighted with fat suppression sequence is the best for detecting lymphoma 
lesions and evaluating treatment efficacy in patients with DLBCL.   
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1. INTRODUCTION 
In clinical diagnoses of patients, imaging has become an important tool in the 
detection and diagnosis of pathological changes. Certain diseases are so critical that 
early detection and diagnosis are important in prescribing proper treatment. One 
area where imaging plays a crucial role is on cancer studies.  
Lymphoma is a type of blood cancer that appears when lymphocytes start to 
duplicate faster than a normal cell or live longer than a normal lymphocyte. 
Lymphoma is divided into two sub groups: Hodgkin lymphoma (HL) and non-
Hodgkin lymphoma (NHL). In Finland, as per Finnish Cancer Registry, lymphoma 
in male and female is the fifth and sixth most frequent neoplasias respectively. The 
statistics also predicts that lymphoma belongs to a class of malignancies with 
noticeable increase in occurrence with time. But, due to the current and future 
advancement in early cancer diagnosis, treatment, and follow-up, the detection of 
cancer in future may be different. Various radiological imaging modalities have 
been used for cancer staging, treatment planning and evaluation of response to 
treatments. And for the better outcome of the treatment and follow-up of patients 
with HDL and NHL, a precise staging and treatment planning using 
multidisciplinary approach is a must. Poorly over-staged malignancy may result in 
unnecessary use of aggressive chemotherapy and beam radiation which could lead 
to development of secondary malignancy. 
Computed tomography (CT) is one of the most commonly used cross-sectional 
imaging modality in the clinical application of early diagnosis and staging of 
lymphoma [1]. As to diagnostic efficiency, CT has a good anatomical resolution, but 
it has lower performance in detecting pathological changes in normal-sized tissue 
structures; it is a challenge to differentiate residual malignancy from fibrosis and 
also does not have a good resolution towards soft tissue structures. In addition, in 
CT there is a possibility to expose patients to higher radiation dose. As metabolic 
characteristic of a tissue has become more vital in cancer studies, positron emission 
tomography (PET) using 2 [fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) has 
become an essential technique in enhancing the staging and follow-up process, and 
for studying the function of the disease behavior in clinical oncology [2,3,4]. The 
most peculiar advantage of this method is that it can provide the metabolic 
information of the malignant tissue which can be used for the analysis of the degree 
of cancer, the response to treatment and for early detection of disease recurrence, 
i.e., cancerous tissues with normal tissue sizes can easily be detected by their 
metabolic activities on the PET image [5, 6, 7]. One of the most pronounced 
disadvantages of PET is that it has low spatial resolution as a result of which it is 
less likely to detect small metastatic nodes (nodes < 4 mm) [8]. Recently, fused 
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FDG-PET/CT has emerged as a very important imaging modality  in lymphoma 
studies by providing high anatomic information from CT which is complemented by 
metabolic information from PET, i.e., cancer cell metabolize glucose much greater 
than the surrounding structures [9], which gives visual and semiquantitative 
information on the PET/CT. This makes PET/CT information to be more accurate 
than PET or CT each alone [10]. In spite of this, PET/CT is found to be expensive in 
routine clinical application [11], and the fact that it has radiation exposure risks to 
patients which may subsequently cause radiation-related cancer [12, 13] makes it 
not highly applicable as it is considered to be.  
Nowadays, magnetic resonance imaging (MRI) is emerging as a promising 
technique in lymphoma studies because of the fact that MRI enables to provide 
different tissue structures with high contrast and spatial resolution for an accurate 
visualization of internal structure, which are vital in diagnosis, staging and follow-
up of cancer, without risking the patient to radiation exposure related malignancies 
and iodinated, potential nephrotoxic contrast agents. The different MRI sequences 
make the modality to be applicable in broad areas of tissue structures. The 
conventional T1 and T2-weighted imaging sequences, the most commonly used 
sequences for soft tissue and related diseases, could alone give a lot of information 
about the target being studied. In addition, recent improvement in MRI technology, 
such as, multi-channel phased array surface coils and parallel imaging acquisition, 
has made a high-spatial-resolution and whole-body MRI (WB-MRI) examination 
possible in a much less imaging time than as it used to be before [14]. Especially, 
lymphomas, such as non-Hodgkin lymphoma (NHL), are so aggressive that they can 
metastasize the whole body, and in such a metastatic situation, the role of WB-MRI 
is crucial [15]. Different MR image analysis techniques, such as volumetric MR 
image analysis and MRI texture analysis have been studied and found to be 
promising in treatment response monitoring and evaluation [16, 17]. Moreover, 
specialized MRI techniques, such as, diffusion-weighted imaging (DWI) with 
apparent diffusion coefficient (ADC) mapping, are able to provide functional 
imaging of tissue structures that let MRI to be applied in the early detection of 
cancerous tumor tissues and to discriminate malignant from benign or differentiate 
residual malignancy from fibrosis or necrosis [18].   
The aim of the thesis is to compare the conspicuity of the most common NHL, 
DLBCL, on the T1-weighted imaging before and after contrast medium 
(Gadolinium) injection, T2-weighted imaging with and without fat suppression and 
to analyze the changes between the MRI sequences before and after one week 
treatment. 
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2. THEORETICAL BACKGROUND 
2.1. Non-Hodgkin lymphoma (NHL) 
Lymphomas are heterogeneous group of malignancies that are estimated to account 
for approximately 3-4% of cancers worldwide and are more frequent in males 
(3.8%) than in females (3%) [19]. It occurs when lymphocytes duplicate 
abnormally. Our body has two main types of lymphocytes that can develop into 
lymphomas: B-lymphocytes (B-cells) and T-lymphocytes (T-cells). These cancerous 
cells can travel to different parts of the body, such as, lymph nodes, liver, bone 
marrow, spleen, blood, and can conglomerate to form tumors. There are two main 
categories of lymphomas: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma 
(NHL). NHLs are the most frequent lymphomas worldwide [19]. 
2.1.1. Etiology of non-Hodgkin lymphoma 
Etiology of NHL is not clearly known. Studies show that it is highly probable that 
NHL evolve from conditions that can genetically disorder the DNA function of a 
cell. HIV/AIDS and organ transplantation have the potential to result in dysfunction 
of T-cell that can result in EBV driven B-cell proliferation [20, 21]. 
2.1.2. Biology of non-Hodgkin lymphoma 
Most of the NHLs originate from B lymphocytes at various stages of differentiation 
of the B cells within the lymphoid tissues called central and peripheral lymphoid 
tissues. Because of the cytogenetic activities, this differentiation of B cells in the 
lymphoid tissues may result in changes in the cytological working principles. An 
abnormal cytogenetic activity can result in the activation of proto-oncogene and 
disorder in the tumour suppressor genes. The translocation of the chromosomes is 
one of the main mechanisms for the activation of the proto-oncogene. This 
activation of proto-oncogene has the potential to produce a cancerous cell [22, 23, 
24]. 
2.1.3. Histology of non-Hodgkin lymphoma  
NHLs are a group of heterogeneous malignancies of the lymphoid system. The 
various clinical behaviors, prognoses, origins and the continuous finding of new 
information about the NHL have resulted in their classification to be changing 
through years. The revised European American classification of the lymphoid 
neoplasm, REAL classification, which was published in 1993 by the international 
lymphoma study group, consisting of outstanding histopathologists from USA, 
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Europe, and Asia, has been widely used. The reproducibility between pathologists, 
finding of new disease types with different clinical behaviors, and validity of the 
REAL classification have been assessed through an accurate clinical environment, 
and its positive outcomes have made the classification to be accepted by the 
oncologists. The REAL classification is updated by WHO and now known as to the 
WHO classification. The WHO classification system is integrated to the newest 
edition of the coding system called the International Classification of Disease-
Oncology (ICD-O). Based on this classification, ICD-O, histological groups of NHL 
are: B-lymphocytic lymphoma, lymphoplasmacytic lymphoma, mantle cell 
lymphoma, mixed small/large cell diffuse lymphoma, large B-cell diffuse 
lymphoma, Burkitt’s lymphoma, follicular grade 2 lymphoma, follicular grade 3 
lymphoma, all follicular combined, marginal zone, mycosis fungicides/sezary’s 
syndrome, other mature T-cell lymphomas, angioblastic T-cell, cutaneous T-cell, 
anaplastic T-cell, other T-cell, NK/null cell, precursor B-cell lymphoma/leukemias, 
and unspecified lymphomas [24, 25, 26, 27]. Broadly NHL is classified into two 
categories:  B-cell lymphomas (accounts approximately 85% of NHLs and develop 
from abnormal B lymphocytes) and T-cell lymphomas (accounts approximately 
15% of NHLs and develop from abnormal T lymphocytes). Follicular lymphoma 
and diffuse large B-cell lymphoma (DLBC) are the two most common B-cell NHL 
[28, 29]. In this work, we are dealing with patients with DLBC lymphoma. DLBC 
NHL can be diagnosed in any age group but are more frequent in older people. It 
usually starts from lymph nodes, such as, lymph nodes of the chest and abdomen, 
and it can also appear in the intestine, bone, brain and spinal cord too. Localized 
DLBC lymphomas account for 33%, and this makes their treatment much easier and 
has a better prognosis than non-localized one. Even if DLBC NHLs are fast growing 
lymphoma types, their response to treatment is very good [27]. 
2.1.4. Signs and Clinical Symptoms of non-Hodgkin lymphoma 
The most common symptoms are: enlarged lymph nodes on the side of the neck and 
collar bones; swollen abdomen due to the enlarged lymph nodes in the stomach that 
can cause pain and appetite loss; and pain in the chest area due to the presence of 
lymphoma in the thymus which result in pain and difficulty in breathing because of 
pressure in the chest (trachea). NHL can also affect the brain, and symptoms, such 
as, headache, thinking problem, personality change, and vision problems can also 
occur [27].  
2.1.5. Staging of non-Hodgkin Lymphoma 
Once the symptoms of NHLs are recognized, a number of diagnostic methods are 
used. After diagnosis of lymphoma is made, it has to be graded appropriately so that 
patients are grouped in the right category that would facilitate to plan a better 
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treatment, predict the likelihood of the response and outcome of the proposed 
treatment plan. The standard staging of NHL is based on the Ann Arbor staging 
system, table.1. The Ann Arbor staging system was primarily designed for HL and 
has some limitations in the staging of NHL. Thus the Ann Arbor staging is not 
important in NHL as it is in HL [30, 31].  
Table1. The modified Ann Arbor staging system for NHL 
Stage                                         Characteristics 
I Involvement of a single lymph node region  
II Involvement of two or more lymph node regions on the same side of 
the diaphragm 
III Involvement of lymph node regions on both sides of the diaphragm 
IV Extra nodal organ involvement  
A Absence of constitutional symptoms 
B Presence of constitutional symptoms 
E Extranodal site 
S Spleen involvement  
X Bulky disease  
      
2.1.6. Treatment of non-Hodgkin lymphoma  
Treatment of NHL usually involves the combination of radiation therapy, single 
agent or combination chemotherapy, immunotherapy, or radioimmunoconjugate 
therapy. Surgery alone can be performed only in conditions where the lymphoma is 
localized. Radiotherapy alone can be used in localized lymphomas or to relieve 
suffering of patient from lymphomas. In children, NHL radiotherapy is not a 
recommended procedure, and it use is restricted only to proven NHL cases of the 
CNS, the head and neck isolated tumour [20]. Chemotherapy is the most common 
therapeutic procedure, especially, in aggressive lymphomas of diffuse large B-cell. 
Monoclonal and radioimmunoconjugate therapy are the standard and most 
commonly used treatment methods in the early stage of indolent lymphomas [32].  
2.1. Diagnostic methods  
In addition to the patient’s history and physical examination, laboratory tests, such 
as, complete blood count, basic blood chemistry, liver and renal function tests, 
erythrocyte sedimentation rate (ESR), albumin, lactate dehydrogenase (LDH) tests 
are performed. Imaging methods are also used for further confirmation of diagnosis, 
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to determine the level of spread of the cancer in the body, staging, treatment 
planning, follow-up and prediction of disease prognosis [22]. The most common 
diagnostic and staging methods are: 
2.1.1. Chest X-ray  
Most NHL involvement of the thoracic cavity, such as, lymphomas of the lymph 
nodes, lung parenchyma, pericardium, pleura, and the chest wall, can easily be 
confirmed with the conventional chest x-ray [30]. From the chest x-ray image, one 
can get information about the involvement of NHL in the chest and mediastinum 
areas of the patient, fig.2.1. 
Also the size of the tumor tissue on the image indicates the bulkiness of the 
tumor (It is bulky if the tumor mass is greater or equal to 33% of the maximum 
intrathoracic cavity) [20]. Even though the chest x-ray procedure is cheap and 
relatively simple, its diagnostic efficiency is hindered because of its lower 
resolution, blurring, and superimposed structures. Because of its difficulties in 
imaging soft tissues and exposing patients to ionizing radiation, its application to 
lymphoma studies is less.   
 
Fig.2.1 Posteroanterior (A) and lateral (B) chest radiographs in a 69-year-old female 
with non-Hodgkin lymphoma manifesting as an ill-defined solitary mass in the left 
lower lobe (arrows)[30]. 
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2.1.2. Computed tomography scan 
Computed tomography is the most common imaging modality used for diagnosis 
and initial staging of lymphomas [1, 33]. A CT produces a tomography image from 
projections of the object at multiple angles by image reconstruction. The rapid 
enhancement of CT technology such as: the introduction of spiral CT, which 
tremendously decrease the scanning time and increase effective use of the contrast 
agent bolus [34], the rapid advent of multidetector row CT, which increase the data 
acquisition and provide thinner slice thickness, more advanced image reconstruction 
methods, made CT to gradually be an important modality in the diagnosis and 
staging of the lymphomas. CT enables tissue structures to be imaged with high 
resolution and better contrast, which are very significant in the diagnosis and staging 
of the lymphomas. Some studies show that CT change the diagnostic information 
obtained from chest x-rays [35, 36]. Patients who are suspected of the NHL usually 
have CT scan, fig.2.2, of the neck, chest, abdomen and pelvis. 
 
Fig.2.2. An 81-year-old man with a peritoneal lymphomatosis by diffuse large B-cell 
lymphoma. CT scan images (A-D) show diffuse peritoneal thickening (black 
arrows), diffuse nodular infiltration of omentum (white arrowheads), bowel wall 
thickening (black arrowheads) and ascites (asterisks) (Kim et al. BMC Cancer 2011 
11:276   doi:10.1186/1471-2407-11-276). 
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The inherent contrast between air and bones lets CT to have a better 
performance in diagnosis and staging of lymphomas related to the thorax and 
abdomen. With the application of contrast medium, it is possible to detect small-
sized extranodal lesions, which are common in NHL. CT scan acquired will give 
information about how many nodes are involved, the size of the tumor and the 
extent of the disease during diagnosis and help in the staging of NHL. The 
evaluation of nodal involvement by CT scan depends on the size criteria. Depending 
on the location of the node, various size values are used. In addition to size criteria, 
shape and clustering of normal-sized lymph nodes are used for diagnosis and staging 
purposes. Noticeable enlargement of the organ, structural change in normal-sized 
organ are used in the diagnosis and staging of the extranodal involvement of the 
lymphoma. Since nodes can be enlarged due to certain other biological processes, 
like inflammation or infection, plus nodes can be small sized but malignant, it is 
difficult for CT to distinguish such phenomena from cancerous one. Differentiation 
of active tumour from fibrous tissue masses after treatment is also a big challenge 
[37, 38, 39]. The diagnostic efficiency of CT is minimal in detecting extranodal 
lymphoma involvement in soft tissues, like brain, central nervous system and bone 
marrow. Disadvantage of CT includes the exposure to ionizing radiation. 
2.1.3. Positron emission tomography (FDG-PET) scan 
PET is a non-invasive diagnostic modality that uses a compound labeled with 
positron emitting radioisotopes as molecular probe to provide tomographic images, 
quantitative parameters and biochemical process of tissues inside the body. F-18 is 
the most common radioisotope used in the clinical application. This isotope is 
incorporated with different substances of biological interest, such as glucose and 
water. During an image acquisition, a biologically active molecule fludeoxyglucose 
(FDG), which is an analog to glucose, will be injected intravenously and distributed 
throughout the body. Normally, cancer cell do have higher glycolytic activity due to 
neoplastic cells. Therefore the FDG uptake by the cancer cell will be very high, 
fig.2.3. After a while, the positron will be emitted from the cancerous cell, combine 
with an electron and annihilation occurs that results in an emission of two photons 
which are detected at the detector to provide a tomographic image of tissue density 
[40].  
As cancer is a biological process, its metabolic property changes with time 
which can be evaluated by using the FDG. This makes PET to be a widely used 
modality in the time course study of lymphomas. It is one of the important imaging 
modality used, especially, in staging and treatment follow-up of patients with NHL. 
An index of glucose metabolism on the PET image called the standardize uptake 
value (SUV), which is the ratio between the measured and expected uptake if FDG 
were distributed evenly throughout the body, is an important parameter used in the 
assessment of the degree of the lymphoma in the follow-up to treatment [16]. 
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Fig.2.3. A Patient with lymphoma, referred for staging. PET images showed intense 
18F-FDG uptake over left sacral region [30].  
 
Study shows that FDG-PET has a high sensitivity in the assessment of 
lymphoma activity in the neck and head region [41, 42]. Since detection of 
malignancy in PET is based on metabolic activity of the cell, it has higher 
performance in differentiating nodes which are enlarged due to lymphoma 
infiltration and that are benign. It is also reliable in the treatment follow-up process 
as it can distinguish active tumor from inactive ones or tissue fibrosis. Some of the 
limitations in FDG-PET are: exposure to ionizing radiation; having poor spatial 
resolution so that small metastatic nodes can be overlooked; lower uptake of the 
FDG may result in false negative finding; and because of the high uptake of FDG in 
non-tumor (benign) tissues or organ like the brain could result in a false positive 
PET finding [43, 44]. 
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2.1.4. Positron emission tomography/Computed tomography (FDG-
PET/CT) scan 
PET/CT is relatively a recent technology which combines the functional and 
anatomical information provided by PET and CT respectively in a single machine, 
fig.2.4.  
  
Fig.2.4 Initial staging with PET/CT in a patient with NHL Extranodal skeletal 
involvement of the right humerus as well as a vertebral body of the thoracic spine 
(biopsy proven) was not detected by CT scans (a, c), but showed pathological [18F] 
FDG uptake on fused PET/CT images (b, d). Suspicious mediastinal lymph nodes 
(arrows) on CT (c) showed pathological [18F] FDG uptake on fused PET/CT (d) 
[45].  
 
In a single examination, PET/CT provides both metabolic- and anatomic-
oriented information of a tissue under investigation. The combination of the two 
imaging modality outperform having CT and PET separately. Patient imaging 
procedure is similar to a single FDG-PET. Image analysis is based on visual and 
semiquantitative methods. Tissue structures with high affinity to FDG and with a 
matching anatomic structure from the CT are considered as abnormal. 
Semiquantitative parameters, like the standardize uptake value (SUV), are used to 
confirm the abnormality of the nodal structures. It provides important information 
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about small-sized lymph nodes which are false negative as per exclusive CT 
evaluation. Organs or tissues which have a higher glucose uptake and show 
increased activity on the FDG-PET image can easily be cross checked with the 
fused CT image and be identified as normal. In addition, benign which are not 
cancerous but shown to be enlarged in CT image, can be compared simultaneously 
with FDG-PET [46]. FDG-PET/CT has an excellent performance in the staging and 
follow-up of NHL involvement of the extranodal sites, such as liver, bone marrow, 
spleen and skin. In the assessment of treatment follow-up, tissue structures which 
are left as inactive after treatment can be clearly identified being not tumor by their 
FDG uptake [47]. Some of the limitations of PET/CT modality are: exposure to 
ionizing radiation, technical difficulties come up as two advanced method operate as 
one, one working principle may interfere with the other such as the application of 
intravenous contrast medium for the CT scan might create artifacts on the PET 
images, misregistration of PET and CT image due to breathing artifacts, and the cost 
for routine clinical application [14, 48].  
2.1.5.  Magnetic resonance imaging (MRI) 
Magnetic resonance imaging (MRI) has already been a very important imaging 
method in diagnostic and research areas of medicine because of its potential to give 
an excellent soft tissue contrast way better than other imaging modalities in the 
absence of any radiation exposure. Moreover, the different kinds of MRI techniques 
available not only provide an image which tells us about the tissue density but also 
give information about properties of the physiochemical environment, flow and 
perfusion of biochemical substances inside the target tissue [49, 50, 51].  
 
The main concept behind MRI imaging is the interaction between an external 
magnetic field B0 and magnetic moment µ  of spinning hydrogen protons which 
results in the precession of proton spins around the B0 axis. The rate at which the 
proton rotate around the axis of the external magnetic field is given by the equation 
called Larmor equation:   
                                  ×≡ γω0 B0                                          
Where, γ  is the gyromagnetic ratio and 0ω  is the angular frequency of the 
proton. 
The application of an external magnetic field B0 result in the alignment of the 
proton in two possible orientations, with or against the direction of B0 which result 
in a net magnetization vector of M in the direction of B0. If an external radio 
frequency signal, RF pulse, with the same frequency as 0ω and with a magnetic field 
of B perpendicular with B0 is applied to the precessing proton, the spins absorb 
energy from the external RF pulse that result in the tilting of the magnetization 
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vector M by certain angleα , it starts to rotate in the x-y plane which results in a net 
transverse magnetization vector of Mxy. An RF pulse of 900 with a proper amplitude 
and duration, flip the longitudinal magnetization vector Mz to transverse plane with 
900 rotations leaving no net magnetization along the B0 axis. Once the RF pulse is 
off, the spins continue to rotate with larmor frequency and thus producing an RF 
signal which can induce a current in a receiver coil. The voltage recorded at the 
receiver is known as MR signal. The measured signal at the receiver coil gradually 
decays as the proton spins dephase or lose their synchronization. This is called free 
induction decay (FID). The proton spin return to their lowest energy state through 
two major important relaxation processes: spin–lattice (T1 relaxation), which results 
in the recovery of the Mz, and spin–spin (T2 relaxation), which results in the decay 
of Mxy. In addition to the spin-spin interaction, the external magnetic 
inhomogeneities contribute to the dephasing of the spin. T*2 is the rate of decay of 
the transverse magnetization because of the field inhomogeneities. The relaxation 
times T1 and T2 are inherent property of a tissue and are the base for image contrast 
in MRI. Each tissue in the human body has different T1 and T2 values; for example, 
fat has a shorter T1 (recover faster) and a shorter T2 (it decays faster) while water has 
a longer T1 and T2. By choosing an appropriate pulse repetition times (TR) and echo 
times (TE), it is possible to change the weights of T1 and T2 in the received signal so 
as to change the contrast between tissues. Selection of the slice and encoding of the 
spatial information in each slice is performed by the gradient coils of the MRI. The 
gradient coil generates time and distance varying magnetic fields which is used for 
the localization of signal from the target. Depending on the axis of image 
acquisition, x- , y- and z-axis gradients are used for section selection, phase and 
frequency encoding. Once the MR system have the information about amplitude and 
spatial location of the signal of the target, it will store it to the K-space, a matrix of 
voxels where the information about the frequency and phase of each spin is stored in 
the MR imaging system and Fourier transformed to get the final MR image [49, 50, 
52, 53]. 
To obtain different kinds of MR images, different combination of RF pulses and 
gradient fields are used. These sequences are called imaging sequence. As the 
dephasing of the spin occurs instantly after the removal of the RF pulse, without the 
proper imaging sequence, it is difficult to get sufficient signal to produce MR image. 
Pulse sequences are used to rephase the spins, decrease the inhomogeneity of the 
external field, control the TR and TE values and thereby generate an echo signal. 
A1800 RF pulse and gradient are the two mechanisms used to rephase spin in MR 
system. By using these two mechanisms, the two most important and basic 
sequences called the spin echo (SE) sequence, which uses 1800 RF pulse, and the 
gradient echo (GRE) sequence, which uses gradient, are used for producing different 
MR images.  
Conventional SE sequences are usually very long while fast or turbo SE 
(FSE/TSE) is used to reduce the image acquisition time in MRI.  In a FSE sequence, 
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instead of using a 1800 RF pulse to produce one spin echo, a train of 1800 RF pulses 
are used after a 900 RF pulse to produce an echo and thereby decrease the number of 
excitation needed and scanning time. The reduction on acquisition time is inversely 
proportional to echo train length (ETL) or turbo factor, which is the number of 1800 
RF pulses and resultant echoes.  
In a GRE sequence, as opposed to 1800 RF pulses, an RF pulse which partially 
tilt the magnetization vector into the transverse plane is used. A bipolar readout 
gradient is used to dephase and rephase the transverse magnetization and thereby 
producing an echo called gradient echo. Even though gradient rephasing is not as 
efficient as RF rephasing, it is faster and has shorter scan time. GRE sequence is 
sensitive to field inhomogeneities and T2* weighted image are mainly dealt with a 
long TE values [50-53]. Gradient sequences can be coherent (refocused) or 
incoherent (spoiled). Both sequences implement a very short TR that is shorter than 
the relaxation time, T1 and T2, of the tissue, and because of this, there will always be 
a leftover transverse magnetization on the successive TRs, and the transverse 
magnetization will remain on a steady state. Thus only T2* dephasing occurs in the 
tissue. The coherent GRE sequence uses a rephasing gradient which rephase the 
dephasing transverse magnetization. This result in the build-up of residual 
transverse magnetization and T2* effect. Thus tissues which have long T2 relaxation 
time, such as, CSF, will show higher signal intensity in this sequence. Whereas in 
spoiled GRE sequence, a spoiler gradient or RF pulse is used to dephase any 
residual transverse magnetization, and this results in contrast of T1 weighting. Thus 
the spoiled GRE sequence is used for generating T1W MR images. This sequence 
uses a very short TR so as to decrease the total image acquisition time and is 
implemented clinically in conditions where a fast image acquisition, such as, whole 
body imaging, dynamic contrast enhanced MR imaging, breath-hold imaging, such 
as in volumetric interpolated breath-hold examination (VIBE), and 3D image 
acquisition are needed [53-56].  
 
Due to the superior localization of soft tissues, MRI is found to be excellent in 
diagnosing lymphoma involvement of brain, spinal cord and bone marrows. 
Clinically, there is no as such accepted golden standard MRI imaging technique. 
Depending on the anatomy of body part, the disease type being dealt, the 
advancement of the MRI on use, and the radiologist experience, different 
radiologists prefer different MRI sequences. Despite this, fat-suppressed, T1-
weighted gradient echo sequences before and after the administration of intravenous 
contrast medium and fat-suppressed T2-weighted short tau-inversion-recovery 
(STIR) sequence are the most commonly practiced MRI sequences [33]. 
 
The T1 and T2-weighted MR imaging with and without contrast agent are the 
most commonly used techniques that are performed in various lymphoma studies. 
Most cancerous tissues have high water content than normal tissues which results in 
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the longer T2 relaxation time and higher signal intensity (brightness) on the MRI 
image. Lower signal intensity on T1-weighted image and higher signal intensity on 
T2-weighted image are the bases for diagnosis of lymphomas on MRI images.  
About 25% to 40% of patients with NHL are expected to have infiltration of the 
bone marrow. Hence, identification of bone marrow involvements of NHL is very 
important for appropriate treatment planning and disease prognosis. Bone marrow 
biopsy, which is an invasive and risky procedure, is still considered as a golden 
standard in the diagnosis of lymphoma involvement of bone marrow. When the 
bone marrow infiltration is localized in small area of tissues, bone marrow biopsy 
procedure, such as iliac crest biopsy, could lead to false-negative results. While 
MRI, especially, whole body MRI, provides the assessment of the large areas of the 
bone, and if combined, it can enhance the diagnostic efficiency of bone marrow 
biopsy. Conventional T1-weighted, short TR, short TE, spin-echo technique (T1-SE), 
conventional T2-weighted, long TR, long TE, spin-echo technique (T2-SE), and 
STIR technique are used for detection of lymphoma in the bone marrow [57,58].  
On T1-SE MRI sequence, the short T1 relaxation time of the fat, due to an 
efficient spin-lattice interaction of proton spin in the bone marrow, results in high 
signal intensity on the MR image while the tumour have longer T1 relaxation time; 
due to the inefficient spin-lattice interaction of proton spins of the tumour; that 
generate a dark signal intensity on the MR image. On the T1-SE MR image, red 
marrow of the bone, which consists of almost half percent of water, appears darker 
than fatty marrow, and this may result in difficulty of detection of the tumour. On 
T2-SE MRI sequence, the fat appears to be dark because of the shorter relaxation 
time T2 while the water rich tumour will appear bright as it has a long relaxation 
time. On T2-SE MRI sequence, the presence of necrosis or inflammatory debris 
which shows tumour activity and appears as bright on MR image makes 
distinguishing of the malignancy difficult [57-60].  
STIR is a contrast generating MRI sequence that is used to suppress the high 
signal intensity from fat so that the signal from tumour tissue is enhanced. In STIR 
spin echo sequence, 1800 RF pulse is applied to flip the magnetization vector from 
fat tissue by 1800. Once the RF pulse is removed, the spin from fat and surrounding 
tissues start to relax and as the net magnetization vector cross the transverse plane at 
a timeτ where the net magnetization for fat becomes zero, the application of a 900 
RF pulse will flip the net magnetization from other tissues. The transverse 
magnetization from other tissues will induce a signal in the coil, but as there is very 
little or no transverse magnetization for fat tissue, signal will not be detected by the 
receiver coil, and this results in dark MR image of fat. Additive T1 and T2 are shown 
in the STIR MR image, and tissues with long T1 and T2 value, like water, will have 
higher intensity (brightness) on the MR image. With STIR imaging sequence, the 
high water containing tumour will have high signal intensity with the fat suppressed 
dark background MR image. The STIR sequence is found to be superior in detecting 
lymphoma of the bone marrow than the T1-SE sequence, and STIR also have the 
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potential to differentiate marrow sclerosis from tumours since marrow sclerosis 
appear dark and tumour appear bright on STIR sequence while both marrow 
sclerosis and tumour appear dark on T1-SE sequence [57-61].  
The combined MRI sequence, STIR and T1-SE, is found to be a sequence which 
gives better image quality for the study of the involvement of lymphoma with bone 
marrow. Recently, the conventional T2-SE and STIR MRI sequence are being 
replaced by the fast spin echo (FSE) sequences, T2-FSE and FSE STIR MRI 
sequences respectively. By implementing the FSE sequences, it is possibly to get as 
good quality as conventional SE sequences with much shorter time. The fat 
suppression MRI sequences expand the dynamic range of the image display by 
suppressing the high signal intensity from fat so as to improve tissue contrast [62-
66]. 
Contrast enhanced (CE) MRI technique is a method used to enhance the 
visibility of targeted tissue. Contrast enhancing material, such as, Gadolinium-
DTPA, increases the T1 relaxation of the target tissue, in such case, the malignant 
tissues, so that non-malignant tissues which are isointense with the malignant on the 
MR image can be discriminated. Infiltration of bone marrow by lymphoma is better 
visualized using contrast enhanced T1-weighted MR than T1-weighted MR sequence. 
In the post treatment evaluation of patients with lymphoma, the enhanced T1 MRI 
can help in differentiating active lymphoma from non-active lymphoma [61, 67]. 
CE-MRI is a method of choice in the study of lymphoma involvement of the central 
nervous system (CNS). NHL is the most common form of CNS lymphomas. In the 
study of lymphoma involvement in the CNS, MRI sequences of T1-weighted SE, T2-
weighted FSE, contrast enhance T1-weighted and fluid-attenuated inversion-
recovery (FLAIR) are mainly used. Because of the high nuclear-to-cytoplasmic ratio 
and dense cellularity of the tumours in the primary CNS lymphoma, it is used in 
differentiating it from other brain malignancies since most of the brain tumors have 
longer T2-relaxation and higher signal intensity on MR image due to high water 
content of the tumor. Studies of lymphoma involvement of CNS show the use of 
contrast agent to the conventional spin echo technique will completely enhance the 
diagnostic efficiency of the MRI. Lesions, which are small and located very close to 
the CSF, are difficult to be detected by T2-weighted MR sequences due to the higher 
signal intensity from the CSF which may obscure the lesions. This can happen 
especially at the early stage of disease, when the lesion is small. FLAIR is a SE-
based MRI technique which is used to create image contrast by nulling the signal 
from CSF. The principle is the same as the STIR sequence which is used for 
suppressing signals from fat. Eliminating the signal from CSF helps in delineating 
lymphomas of small size, located adjacent to CSF with hyperintense signal on MR 
image. The ability of FLAIR in detecting small-sized lesion at early stage is crucial 
and contributes to the staging, treatment planning and also improves the prognosis 
of the patient [68-73].  
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Enlargement of mediastinal lymph nodes, parenchymal anomaly, and 
pericardial, pleural, and chest wall involvement of the lymphoma, called thoracic 
lymphoma, are frequently studied before and after contrast material methods using 
T2-weighted FSE and T1-weighted SE (T1W-SE). On T1W-SE, enlarged lymph 
nodes will appear as hypointense to fat, and they appear as hyperintense or 
isointense to fat on T2W-SE [74].  In the treatment follow-up of patients with 
mediastinal lymphoma, tissues which show high signal intensity with a homogenous 
pattern on a T2W image corresponds to be an active tumour while the same tissue 
appears in a homogenous low intensity pattern on a T1W MR image. A mixed 
pattern of high and low signal intensity on the T2W images often corresponds to a 
mixture of active tumour and some other tissues, such as, fibrosis, and inflammation 
that often appear after early treatment. A homogenous pattern of hypointense 
intensity on T2W images is characteristic of inactive fibrous tissue. Tissues which 
show high homogenous enhancement on T1W after contrast are assumed to be active 
tumour while those tissues which show mixed enhancement correspond to the 
presence of mixed tissue, active tumour and inactive fibrosis, or inflammation 
whereas tissues with no or low enhancement correspond to the inactive fibrosis. 
MRI has a better diagnostic efficiency in the treatment follow-up if it is used after 6 
months of treatment [75, 76, 77]. 
 The evaluation of thoracic lymphoma using MRI is liable to artifact that arises 
due to the movement of the thoracic and abdominal region while breathing which 
results in blurring and loss of image resolution. In order to maintain the quality of 
the output image, various MRI techniques are clinically implemented. In the 
simplest imaging technique called breath-hold imaging, the patient will hold his/her 
breath for a short period of time which is efficient in reducing the artifact.  For this 
technique we need a fast image acquisition technique as conventional spin echo 
(CSE) is not fast enough for this purpose. A fast imaging technique such as Turbo 
SE, HAST (half-Fourier single-shot turbo spin echo) techniques are used. HAST is 
similar to TSE sequences with a single-shot RF pulse. In this sequence, after a single 
RF excitation, a bit more than half of the k-space will be acquired and the rest will 
be filled by mirror symmetry of the k-space. Fourier transformation of the k-space 
will provide us the HAST MR image. Because of its higher speed, HAST imaging 
technique is used for breath-holding MR studies [78, 79]. In addition, volumetric 
breath-hold examination (VIBE) is a new gradient-echo method that uses the spoiled 
GRE sequence and provides a short image acquisition time which can be used for 
imaging of abdominal regions so as to remove movement-associated artefacts of the 
MR image [56].   
Lymphomas are a kind of disease that can infiltrate throughout the body. Almost 
40% of skeletal metastases involve the appendicular skeleton which needs an 
imaging method that covers anatomy of the whole body. MRI has proven to be 
superior in diagnosing bone and bone marrow involvement of malignancy [80, 81]. 
Rapid advancements in hardware of scanner (multi-receiver channel scanner), 
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surface coils (multiple phased-array coil), and the development of various new 
imaging sequence and acquisition methods (parallel image acquisition technique, 
PI), have made the whole body MRI (WB-MRI) technique as an alternative to 
multimodal imaging methods and be applied in routine clinical studies of malignant 
lymphoma within a reasonable scan time. As lymphoma involvement of the bone 
marrow is common in NHL, the role of WB-MRI in the staging process is 
indisputable. Even if there is no standard sequence with a considerable minimal time 
for WB-MRI method, the STIR sequence is found to be more sensitive [82, 83]. 
Depending on the anatomical location to be imaged, different MRI protocols can be 
used. In dedicated MRI, T1-weighted SE and STIR imaging sequence are found to 
be important in the assessment of lymphomas of the bone marrow and lymph nodes 
[84, 85, 86]. Hence, in WB-MRI lymphoma studies, coronal T1-weighted FSE and 
coronal STIR imaging sequences are used in the assessment of the head/neck, 
thorax, abdomen/pelvis and lower extremity regions of the body.  In order to reduce 
the motion artefact in the thorax and abdomen region, fast and breath-hold imaging 
sequences, such as, T1-FSE, HAST, and VIBE are implemented. Since coronal MR 
image cannot provide all the necessary information, additional axial oriented image 
of the head/neck, thorax, and abdomen/pelvis regions will be taken. In addition, 
contrast enhanced (CE) axial T1-FSE image of the head/neck, CE axial STIR image 
of the thorax, CE sagittal STIR image of the spin, and CE STIR or T1-FSE image of 
the abdomen region will complement the diagnosis process [82, 87].  
 
Most of the imaging methods that are used clinically in diagnosis, staging, and 
treatment follow-up of patients with nodal lymphoma mainly rely on morphological 
appearances, such as, size, border, and shape of the nodes in the image. But it is also 
true that even small-sized lymph nodes can be infiltrated by cancerous cells and 
lymph nodes can become enlarged with some other biological process like 
inflammation, and thus even after treatment, the size criteria could lead to a false 
analysis. Even conventional MRI analysis of lymphoma depends on the intensity of 
the target tissues, but in the same way, inflammation, necrosis, and cysts can show 
tumor activity so that the analysis still have to be based on size criteria. Studies 
show that this challenge can be solved with recent application of diffusion theory on 
MRI. Diffusion of water molecule inside tissues is affected by the normal cellular 
interaction within the tissues. Nodes that are involved with malignant lymphoma 
will have higher cellular structure which restricts the intra- and extracellular 
movement of water molecule in the cellular environment [88, 89, 90]. Diffusion-
weighted imaging (DWI-MRI) is a technique which can isolate areas with restricted 
diffusion (slow diffusion of proton), lymphomatous tissue, from unrestricted (rapid 
diffusion of protons). Fast imaging sequences, such as, echo-planner or fast GRE 
sequences and two equal gradient pulses are mainly used in DW-MRI. Echo planner 
imaging (EPI) is a very fast imaging sequence which uses a single echo train to fill 
all lines of the k-space. The mechanism of producing a diffusion-weighted image is 
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that before image acquisition, a dephasing and rephasing gradient are applied, and if 
the spin that are in phase are dephased by the dephasing gradient, the signal 
intensity will decrease, and if the same but opposite gradient is applied, the spin will 
be rephrased again, and this results in high signal intensity on MR image. This 
happens in a condition where there is restricted motion of protons between the times 
of the applied gradients, which is in cancerous tissues. Whereas, in normal tissues, 
spin motion is not restricted and spin undergoes phase shift which results in 
decrease of intensity on the MR image [50, 55, 91, 92, 93]. The presence of high 
intensity on the DWI-MR image could be from the longer T2 effect (normal tissues 
having longer T2 decay time), the phenomenon called T2 shine-through, which can 
cause wrong diagnosis. Apparent diffusion coefficient (ADC) mapping is a 
technique that is derived from ADC maps. An ADC map is calculated 
mathematically by comparing images obtained with DW against without DW. In an 
ADC map, areas of restricted diffusion (cancerous tissue) appears as dark whereas 
normal tissues appear bright [55], for example, DLBCL, the most common form of 
NHL, shows high signal intensity in DWI and low signal in ADC mapping. The 
ADC value is not dependent of the magnetic field strength and can remove the T2 
shine-through effect. Hence to confirm the diagnosis of diffusion restriction, 
comparing DWI against ADC mapping is important [14]. Studies show that the 
challenge in differentiating between the benign and malignant lymphadenopathies 
can be solved by DWI incorporated with ADC mapping [88, 89, 91, 93]. DWI with 
ADC mapping can be used in treatment follow-up of patients with lymphoma. Study 
shows that DWI with ADC mapping is capable of providing comparable diagnostic 
results as the PET/CT imaging method [14].  
 
2.1.6. Biopsy  
It is a procedure where a piece of tissue is taken from the cancer suspected part of 
the body and examined, usually, under microscope. A pathologist will examine the 
tumor tissue under microscope and study the features of the cells in the surrounding 
tissue and examine in detail the antigens on the surface of the cells [22, 31, 94]. 
Biopsy is an important procedure to confirm the type, histopathology and 
confirmation of the diagnostic results of other procedures of lymphoma. The most 
common biopsies are: 
Excisional or incisional biopsy: A biopsy where a surgical removal of the entire 
node is performed (excisional biopsy) or small part of the tumor is removed 
(incisional biopsy) for further examination. It is a preferred biopsy procedure 
because it preserves the architecture of the node and gives a relatively large sample 
for examination [22, 31, 94].  
Needle biopsy: In a condition where the suspected tissue is deep inside the body, 
a fine needle is inserted into the tissue, called fine needle aspirate (FNA) and sample 
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is removed for examination. A larger tissue can be taken by a bore needle called 
core needle biopsy. For deeper tissues, an image (CT or ultrasound) guided biopsy is 
performed. FNA is usually performed to study for patients already diagnosed of 
lymphoma or in the disease relapse [22, 31, 94]. 
Bone marrow aspirates and biopsy: They are performed to check whether there 
is bone marrow involvement of the lymphoma or not. As bone marrow involvement 
by NHL is frequent, it is highly recommended for NHL patients [22, 31, 94].  
 
2.2. Image analysis method  
The fast evolving technology of MRI makes it promising for better diagnosis, 
treatment, and follow-up of patients. Clinically, once images are acquired, 
qualitative, quantitative, or both, image analyses are used in the disease diagnosis 
process and in the evaluation of information content of the image.  
2.2.1. Qualitative MRI image analysis  
In a clinical environment, diagnosis and evaluation of diseases from MRI image are 
usually based on qualitative image analysis methods. Qualitative image analyses are 
subjective, experience-based, and are usually based on visual assessment of the 
acquired image for an abnormal feature in the image such as morphological 
appearances, including size, border and shape of the tissues or nodes on the acquired 
images. A lot of research has been done to compare the different MRI sequences for 
different disease diagnoses or evaluation of responses to treatment.  Many have used 
qualitative method to compare the different sequences. Visually comparing the 
sequences and giving rank have been used in a lot of studies.  
2.2.2. Quantitative MRI image analysis  
Quantitative image analyses involve different techniques, such as, texture analysis 
of image to extract certain features and parameters, and curve fitting between image 
sets acquired at different time points to extract quantitative information, such as, 
water content or relaxation time. Quantitative image analyses are more reliable and 
less prone to intra- and inter-observer variability, but are usually implemented on 
research level [95]. 
Contrast values collected from different MRI sequences are important 
quantitative parameters for comparing MRI sequences. In addition to morphology, 
contrast plays a vital role in the disease diagnoses, staging and follow-up of 
lymphoma patients. The relaxation times in MRI are inherent property of a tissue 
and are the bases for image contrast. Each tissue in the human body has different T1 
and T2 relaxation values and hence different intensity on different sequences. Thus 
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the conspicuity of tissue can be varied by using different MRI sequences. Upon 
visual analysis, the sequence which depicts the target tissue with higher contrast or 
makes the target tissue distinguishable from other surrounding tissue is used in the 
diagnosing process.       
   
The contrast level of a target tissue can be defined in different ways. In this 
study the Weber contrast,  
   C =    Sa−SbSb                        (1)  
is used, where   𝑆𝑎 and 𝑆𝑏 are the signal intensities of the target and the reference , 
surrounding or adjacent tissue. 
 
Thus contrast, a simple quantitative parameter, is measured from MRI images 
and is less prone to intra- and inter-observer variability. 
 
Once the contrast ratio is calculated for the different MRI sequences, the data 
can be analyzed using different statistical techniques. Depending on the data, 
parametric or non-parametric statistical methods are used. The parametric method 
usually assumes that the data is drawn from a normally distributed population 
whereas the nonparametric make no assumption about the population where the 
sample is drawn from. Nonparametric statistical methods are preferred when the 
data is not normally distributed or in a condition when the numbers of data are 
small. Wilcoxon Signed Rank Test is a nonparametric statistical method that is used 
for comparison of two paired data on repeated measurements. In this work, SPSS 
statistical software is used for analyses.  
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3. MATERIAL AND METHODS 
3.1. Patient 
In this study MRI images of eighteen patients (thirteen men and five women; mean 
age, 62 years) with aggressive DLBC NHL are used. Patients were part of a big 
research project work on aggressive lymphoma study. The inclusion and exclusion 
criteria are briefly described in reference 14. The study is approved by the Ethics 
Committee of Tampere University Hospital. 
 
All patients had physical examination, standard laboratory tests for lymphomas. 
In addition, unilateral bone marrow aspiration and trephine biopsy were performed 
on each patient. Pathological samples were reviewed by expert hematopathologists 
and classiﬁed according to the WHO/Revised European–American Lymphoma 
classification of lymphoid neoplasm [14]. 
 
All but patient three, ten and eighteen were imaged by MRI before enrolment to 
treatment (E1) and one week after the first dose of chemotherapy (E2). Patient three, 
eleven and fifteen underwent only MRI scanning before treatment (E1). In addition 
patient ten had no T2W fat suppression MR sequence.  
3.2. MRI acquisition 
MRI image was acquired using a 3-T MR System (Siemens Trio-Tim, Erlangen, 
Germany) with the manufacturer’s body and spine array coils. The body matrix coil 
had six elements and dimensions of 322 mm ×520 mm ×40 mm (L × W × H). The 
body matrix coil was used in combination with the spine matrix coil that had 24 
elements and dimensions of 185 mm× 485 mm× 33 mm (L × W×H). The 
appropriate number of spine coil elements was connected to cover the anatomy of 
interest. In addition, a neck coil was used for examination of the cervical region. It 
had four elements  with  a patient  bore  of  225 mm× 205 mm  (H × W) and  coil  
outer  dimensions  of  190 mm×330 mm×332 mm (L× W×H). The MRI 
examination consisted of whole-body screening from the level of the skull base to 
the floor of the pelvis in the coronal plane using a parallel acquisition technique that 
allows for the improvement of spatial resolution without prolonging data 
acquisition. Because the coronal imaging had a limited field of view to cover the 
whole body, the upper and lower body trunks were imaged separately in the coronal 
plane.  
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In this study MRI protocols, an axial T1-weighted, three-dimensional, volumetric 
interpolated breath-hold examination with fat suppression, before and after 
gadolinium tetraazacyclododecanetetraacetate (0.2 ml/kg Dotarem) injection, and 
axial T2-weighted TSE imaging, once with and once without fat suppression, are 
used. Before contrast administration, DWI was acquired using a single-shot echo-
planar sequence in the axial plane with two b values (0 and 800 s/mm2). ADC map 
is calculated from the DWI. In addition to the axial MR images, the coronal, sagittal, 
DWI, ADC map and 3D MR images of the patients are also used for the accurate 
localization of the lesion. Below, in figures 3.1-3.4, are examples of images of the 
different MRI protocols. 
 
 
   
  
Fig 3.1 Abdominal region lymphoma in a 68-
years old man patient: Axial T1-weighted 
image showing a large tumor on the left side. 
Fig 3.2 Abdominal region lymphoma in a 
68-years old man patient: Axial T1-
weighted image after contrast injection 
showing enhanced tumor. 
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Fig 3.3 Abdominal region lymphoma in a 
68-years old man patient: Axial T2-
weighted image showing a large tumor on 
the left side. 
Fig 3.4 Abdominal region lymphoma in a 68-
years old man patient: Axial T2-weighted with 
fat suppression image showing more contrast 
tumor on the left side 
 
3.3. MRI image analysis  
All the MR images were viewed on a Picture Archiving and Communication System 
workstation. The mean signal intensity of the lesion, which is selected manually by 
the computer mouse, from the different MRI sequences is measured. Circular or free 
hand drawing is used for selection of the region of interest (ROI). Enclosing the ROI 
with circle or free hand drawing generates the mean signal intensity value of pixels 
enclosed by the ROI.  
 
Because absolute signal intensity measurements are potentially subject to 
variation, dependent on the position of the ROI in relation to the surface coil and the 
amplifier gain of the image reconstruction circuitry, normalized lesion to normal 
tissue signal intensities within each MRI sequences are used. The normalized 
intensities are contrast ratio which conveys information about the performance of 
each sequence in delineating a lesion from normal tissue. 
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𝐶 = 𝑆𝑙−𝑆𝑛 
𝑆𝑛
                               (2) 
 
Where  𝐶  is the normalized contrast intensity ratio,  𝑆𝑙  is the absolute lesion 
signal intensity and 𝑆𝑛 is the absolute normal tissue signal intensity, which in this 
case is the vertebral tissue. 
 
Once the target lesion is identified visually in each MRI sequence, ratios were 
calculated comparing the signal intensity value of target lesion with the signal 
intensity value of the normal tissue. Table 3.1 and table 3.2 show the absolute and 
normalized signal intensities of the four MRI sequences at time point E1 and E2 
respectively. The normal tissue is chosen from the same slice as the lesion and as the 
vertebral tissue is easily detectable from different MRI sequences and its mean 
signal intensity value is fairly the same; it is found appropriate to make the vertebral 
tissue as a reference tissue against the lesion. Examples of images of MRI are shown 
in figures 3.5-3.8 below.  
 
  
Fig 3.5 Abdominal region lymphoma 
in a 68-years old man patient with a 
region of interest in tumor and normal 
tissue on Axial T1-weighted 
Fig 3.6 Abdominal region lymphoma in a 
68-years old man patient with a region of 
interest in tumor and normal tissue on 
Axial T1-weighted image after contrast 
injection. 
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Fig 3.7 Abdominal region lymphoma in a 
68-years old man patient with a region of 
interest in tumor and normal tissue on 
Axial T2-weighted image. 
Fig 3.8 Abdominal region lymphoma in a 
68-years old man patient with a region of 
interest in tumor and normal tissue Axial 
T2-weighted with fat suppression. 
 
  
 
 
 
 
 
 
 
 
26 
 
Table 3.1.  Absolute and normalized signal intensities of the four MRI sequences at time point E1. 
 
 
 
 
 
 
 
 
 
 
 
 
E1T1=E1T1Ld- E1T1Bd/ E1T1Bd;   
E1T1C= E1T1_cLd- E1T1_cBd / E1T1_cBd;  
E1T2= E1T2Ld - E1T2Bd / E1T2Bd; 
E1T2fs= E1T2_fsLd - E1T2_fsBd / E1T2_fsBd; 
Target Sex Age E1T1Ld E1T1Bd E1T1 E1T1_cLd E1T1_cBd E1T1C E1T2Ld E1T2Bd E1T2 E1T2_fsLd E1T2_fsBd E1T2fs  
Abdomen F 56 182 260 -.30 412 269 .53 435 495 -.12 337 166 1.03  
Abdomen M 61 208 137 .52 446 240 .86 389 455 -.14 398 244 .63  
Neck M 57 189 289 -.35 498 372 .34 581 290 1.00 581 166 2.50  
Neck F 51 215 321 -.33 650 458 .42 563 343 .64 426 147 1.90  
Neck M 78 155 175 -.11 297 231 .29 224 158 .42 221 59 2.75  
Neck M 56 286 332 -.14 691 527 .31 716 366 .96 593 169 2.51  
Abdomen F 54 205 216 -.05 490 537 -.09 630 568 .11 374 277 .35  
Neck F 32 216 313 -.31 410 418 -.02 754 1160 -.37 550 159 2.46  
Abdomen M 48 200 167 .20 394 301 .31 551 531 .04 445 86 4.17  
Thorax M 70 354 355 .00 666 487 .37 173 193 -.10     
Abdomen F 74 197 177 .11 388 347 .12 586 645 -.09 482 118 3.08  
Neck M 75 249 317 -.21 600 448 .34 696 538 .29 642 145 3.43  
Abdomen M 47 182 115 .58 288 180 .60 372 347 .07 301 54 4.57  
Thorax M 66 501 533 -.06 816 782 .04 469 411 .14 347 191 .82  
Abdomen M 68 191 156 .22 369 349 .06 590 653 -.10 425 92 3.62  
Thorax M 66 210 118 .78 441 189 1.33 474 281 .69 356 59 5.03  
Abdomen M 76 137 105 .30 334 179 .87 477 562 -.15 419 71 4.90  
Abdomen M 79 245 171 .43 568 305 .86 717 469 .53 541 113 3.79  
 
E1,time point E1;T1, T1 W MRI sequence; Ld, signal intensity of the lesion (Lesion density);Bd, signal intensity of the bone(vertebrae); 
T1_C,  T1 W  MRI sequence  with contrast agent; T2, T2 W MRI sequence; fs, fat suppression. 
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Table 3.2.  Absolute and relative signal intensities of the four MRI sequences at time point E2.  
 
E2T1=E2T1Ld- E2T1Bd/ E2T1Bd;   
E2T1C= E2T1_CLd- E2T1_CBd / E2T1_CBd;  
E2T2= E2T2Ld – E2T2Bd / E2T2Bd; 
E2T2fs= E2T2_fsLd – E2T2_fsBd / E2T2_fsBd; 
Target Sex Age E2T1Ld E2T1Bd E2T1 E2T1_CLd E2T1_CBd E2T1_C E2T2Ld E2T2Bd E2T2 E2T2_fsLd E2T2_fsBd E2T2fs  
Abdomen F 56 204 167 .22 458 240 .91 461 632 -.27 332 190 .75  
Neck M 57 212 324 -.35 559 441 .27 461 399 .16 450 148 2.04  
Neck F 51 305 361 -.16 779 544 .43 559 461 .21 408 267 .53  
Neck M 78 294 257 .14 588 439 .34 501 239 1.10 508 102 3.98  
Neck M 56 478 342 .40 992 691 .44 583 279 1.09 642 337 .91  
Abdomen F 54 239 248 -.04 568 726 -.22 816 974 -.16 581 585 -.01  
Neck F 32 264 364 -.27 549 674 -.19 732 532 .38 671 247 1.72  
Abdomen M 48 222 159 .40 447 333 .34 643 516 .25 473 110 3.30  
Abdomen F 74 204 131 .56 385 311 .24 614 674 -.09 387 88 3.40  
Neck M 75 317 314 .01 730 423 .73 567 411 .38 543 188 1.89  
Abdomen M 47 240 134 .79 474 282 .68 366 450 -.19 324 154 1.10  
Thorax M 66 912 556 .64 1416 659 1.15 317 621 -.49 317 621 -.49  
Abdomen M 68 284 149 .91 448 318 .41 710 594 .20 550 119 3.62  
Thorax M 66 213 106 1.01 370 196 .89 410 323 .27 247 65 2.80  
Abdomen M 76 206 146 .41 305 210 .45 421 489 -.14 383 110 2.48  
E2, time point E2 ; T1, T1 W MRI sequence; Ld, signal intensity of the lesion (Lesion density);Bd, signal intensity of the bone(vertebrae); T1_C,  T1 W  
MRI sequence  with contrast agent; T2, T2 W MRI sequence; fs, fat suppression. 
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3.4. Statistical analysis  
The normalized mean signal intensities, contrast ratio, were used to compare the 
sensitivity of each sequence in the detection of the lesion. To find out whether there 
is a significant difference between the different groups of MR imaging sequences, a 
nonparametric statistics test, Wilcoxon Signed Rank Test, is performed on the 
normalized signal intensities. Overall significance difference is determined based on 
the p value. If the p value is less than or equal 0.05, then there is a significant 
difference in the mean normalized signal intensity between the sequences. If the p 
value is above 0.05, then there is no significant difference between the sequences. 
 
A significant level (p value) of less than 0.05 is considered as statistically 
significant. The statistical analyses were performed using SPSS software. 
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4. RESULTS 
Normalized signal intensities calculated from MR images of the patients at E1 and 
E2 were statistically analyzed. As the sample data collected are small, a non-
parametric statistics technique called Wilcoxon Signed Rank Test is conducted to 
evaluate and compare the different MRI sequence on the calculated mean 
normalized signal intensities at each time points, E1 and E2.  
 
At the time point E1, all patients had gone through the four imaging protocols 
and one patient had not had the T2W fat suppression MRI sequence.  After 
treatment, E2, sixteen patients, from the eighteen patients, MRI data was used for 
the analyses. All the sixteen patients at E2 had all the four imaging protocols. In 
nine patients the target lesions were located on the abdomen region and six were on 
the neck and the rest three were in the thorax. All patients had DLBCL. 
4.1. Comparison between sequences at time point E1 
The box plot, figure 4.1, shows that the mean normalized signal intensity 
distribution for T2W fat suppression technique is much higher than the rest of the 
sequences and T1W with contrast follows the second. The intensity distribution for 
the T1W before contrast agent and T2W without fat suppression looks very similar. 
There were eighteen patients in the T1, T1C and T2-weighted MRI sequences. One of 
the patient had no T2fs weighted MRI sequence.  
 
Tables 4.1 show the mean contrast ratio of the four sequences at the time point 
E2. It is clearly seen that the mean signal contrast ratio is much higher on the T2W 
fat suppression MRI sequence. 
 
Having established that the mean signal contrast ratio is much higher in the T2W 
fat suppression MRI sequence and also in the distribution box plot, a Wilcoxon 
Signed Rank Test is conducted to evaluate if this difference is really significant.  
Table 4.2 shows the output from the Wilcoxon Signed Rank Test and it can be seen 
that the p value is substantially much less than the specified p value of 0.05. This 
implies that there is really a significant difference in the normalized signal contrast 
ratio between the T2W fat suppression and the other MRI sequence. That is the 
conspicuity level of the lesion is much higher in the T2W fat suppression than the 
other MRI sequence. 
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Figure 4.1. Box plot showing the distribution of the normalized mean signal           
intensities from the four different sequences at time point E1. T2W fat   
suppression technique shows superior contrast ratio. 
 
 
 
 
 
 
 
 
Table 4.2 Wilcoxon Signed Ranks Test, there is a statistically significant 
difference between E1T2fs ↔ E1T1, E1T2fs↔E1T1C, E1T2fs ↔E1T2.   
Table 4.1 A descriptive statistic at time point E1shows that T2fs have the highest 
normalized mean signal intensity. 
                                                       Descriptive Statistics 
  N Minimum Maximum  Mean Std. Deviation 
E1T1 18 -.35 .78 .0714 .34348 
E1T1C 18 -.09 1.33 .4186 .37089 
E1T2 18  -.37 1.00 .2119 .40552 
E1T2fs 17 .35 5.03 2.7967 1.48836 
      
Wilcoxon Signed  Ranks Test 
Sequences E1T2fs ↔ E1T1 E1T2fs↔E1T1C E1T2fs ↔E1T2 
p value          .000         .000           .000 
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4.2. Comparison between sequences at time point E2 
The box plot, figure 4.2, shows that the mean normalized signal intensity 
distribution for T2W fat suppression technique is much higher than the rest of the 
sequences and T1W with contrast follows the second. The intensity distribution for 
the T1W before contrast agent is higher than T2W without fat suppression.  Fifteen 
patients were analyzed for the four MRI protocols.  
 
Tables 4.3 show the mean contrast ratio of the four sequences at the time point 
E2. It is clearly seen from table 4.3 that the mean signal contrast ratio is much 
higher on the T2W fat suppression MRI sequence. 
 
Knowing that the mean signal contrast ratio is much higher in the T2W fat 
suppression MRI sequence and also in the distribution box plot, a Wilcoxon Signed 
Rank Test is conducted to evaluate if this difference is really significant.  Table 4.4 
shows the output from the Wilcoxon Signed Rank Test and it can be seen that the p 
value is still substantially much less than the specified p value of 0.05. This implies 
that there is really a significant difference in the normalized signal contrast ratio 
between the T2W fat suppression and the other MRI sequence after treatment. That 
is the conspicuity level of the lesion is much higher in the T2W fat suppression than 
the other MRI sequence at time point E2. 
 
 
Figure 4.2. Box plot showing the distribution of the normalized mean signal 
intensities from the four different sequences at time point E2. T2W fat suppression 
technique shows superior contrast ratio. 
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Table 4.4 Wilcoxon Signed Ranks Test; there is a statistically significant difference 
between E2T2fs↔E2T1, E2T2fs↔E2T1C, and E2T2fs↔E2T2. 
Wilcoxon Signed Ranks Test 
 
 
4.3. Comparison of sequences between time point E1 and E2 
Comparison between T1W MRI sequences before contrast administration 
between the time point E1 and E2 
The box plot, figure 4.3, shows that the mean normalized signal intensity 
distribution for T1W MRI technique is much higher at the time point E2, after 
treatment, than at time point E1, before treatment. Eighteen patients before 
treatment and fifteen patients after treatment were analyzed. The mean normalized 
signal intensities at time point E1 and E2 can be seen from table 4.5. The mean 
signal intensity has shown an increment after treatment. 
 
Once knowing that the mean signal contrast ratio is higher on the T1W MRI 
sequence and also in the distribution box plot at the time point E2, a Wilcoxon 
Signed Rank Test is conducted to evaluate if this difference is really significant.  
Table 4.6 shows the output from the Wilcoxon Signed Rank Test and it can be seen 
that the p value is less than the specified p value of 0.05. This implies that there is 
really a significant difference in the normalized signal contrast ratio between the 
T1W MRI sequence before and after treatment.  
 
 
 
Table 4.3 A descriptive statistic at time point E2 shows that T2fs have the highest 
normalized mean signal intensity. 
Descriptive Statistics 
 N Minimum Maximum Mean Std. Deviation 
E2T1 15 -.35 1.01 .3115 .42301 
E2T1C 15 -.22 1.15 .4576 .37533 
E2T2 15 -.49 1.10 .1789 .45011 
E2T2fs 15 -.49 3.98 1.8677 1.38519 
      
Sequences E2T2fs↔E2T1 E2T2fs↔E2T1C E2T2fs↔E2T2 
p value 0.002 0.004   0.002 
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Figure 4.3. Box plot showing the distribution of the normalized mean signal 
intensities from the T1w imaging sequences at time point E1 and E2. T1W imaging 
technique after treatment has a higher contrast ratio than before treatment. 
 
Table 4.5 A descriptive statistic at time point E1and E2 shows that after treatment 
the normalized mean signal intensity is higher than before. 
 
Table 4.6 Wilcoxon Signed Ranks Test; there is a statistically significant difference 
between E2T1↔E1T1. 
Wilcoxon Signed Ranks Test 
Sequences E2T1↔E1T1 
p value      0.001 
Descriptive Statistics 
 N Minimum Maximum Mean Std. Deviation 
E1T1 18 -.35 .78 .0714 .34348 
E2T1 15 -.35 1.01 .3115 .42301 
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Comparison between T1W MRI sequences after contrast administration 
between the time point E1 and E2 
The box plot, figure 4.4, shows that the mean normalized signal intensity 
distribution for T1WC MRI technique is a bit higher at the time point E2, after 
treatment, than at time point E1,before treatment. Eighteen patients before treatment 
and fifteen patients after treatment were analyzed. The mean normalized signal 
intensities at time point E1 and E2 can be seen from table 4.7. The mean signal 
intensity has shown a small increment after treatment. 
  
Even if the mean signal intensity distribution on the box plot and in the table 4.7 
has shown a bit increment, this increment was not significant (p >0.05) as seen in 
the table 4.8. 
 
 
Figure 4.4. Box plot showing the distribution of the normalized mean signal 
intensities from the T1WC imaging sequences at time point E1 and E2. T1WC 
imaging technique after treatment has a higher contrast ratio than before treatment. 
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Table 4.7 A descriptive statistic at time point E1and E2 shows that after treatment 
normalized mean signal intensity is a bit higher than before. 
Descriptive Statistics 
 N Minimum Maximum Mean Std. Deviation 
E1T1C 18 -.09 1.33 .4186 .37089 
E2T1C 15 -.22 1.15 .4576 .37533 
 
Table 4.8 Wilcoxon Signed Ranks Test; there is no statistically significant difference 
between E2T1C↔E1T1C. 
Wilcoxon Signed Ranks Test 
Sequences E2T1C ↔ E1T1C  
p value      0.496 
 
Comparison between T2W MRI sequences without fat suppression between 
the time point E1 and E2 
The box plot, figure 4.5, shows that the mean normalized signal intensity 
distribution for T2W MRI technique is higher at the time point E1, before treatment, 
than at time point E2, after treatment. Eighteen patients before treatment and fifteen 
patients after treatment were analyzed. The mean normalized signal intensities can 
be seen from table 4.4. The mean normalized signal intensity value before and after 
treatment can be seen in the table 4.9 below. 
 A nonparametric statistical analysis, Wilcoxon Signed Ranks Test, is conducted 
to see if the difference in the mean signal contrast ratio between the pre and post 
treatment is significant and the result is shown in the table 4.10 below. From the 
table 4.10 it is clearly seen that the difference is not significant (p >0.05). 
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Figure 4.5. Box plot showing the distribution of the normalized mean signal 
intensities from the T2W imaging sequences at time point E1 and E2. T2W imaging 
technique before treatment has a higher contrast ratio than after treatment. 
 
Table 4.9 A descriptive statistic at time point E1and E2 shows that after treatment 
the normalized mean signal intensity is less than before. 
Descriptive Statistics 
 N Minimum Maximum Mean Std. Deviation 
E1T2 18 -.37 1.00 .2119 .40552 
E2T2 15 -.49 1.10 .1789 .45011 
 
Table 4.10 Wilcoxon Signed Ranks Test; there is no statistically significant 
difference between E2T2↔E1T2. 
 
 
 
                                       Wilcoxon Signed Ranks Test  
Sequences E2T2 ↔ E1T2 
p value 0.650 
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Comparison between T2W MRI sequences with fat suppression between the 
time point E1 and E2 
The box plot, figure 4.6, shows that the mean normalized signal intensity 
distribution for T2Wfs MRI technique is higher at the time point E1, before 
treatment, than at time point E2, after treatment. Seventeen patients before treatment 
and fifteen patients after treatment were analyzed. The mean normalized signal 
intensity before and after the treatment is shown in the table 4.11. 
Once knowing that the mean signal contrast ratio is lower on the T2Wfs MRI 
sequence and also in the distribution box plot at the time point E2 than at time point 
E1, a Wilcoxon Signed Rank Test is conducted to evaluate if this difference is really 
significant.  Table 4.12 shows the output from the Wilcoxon Signed Rank Test and 
from the table it can be seen that the p value is substantially less than the specified p 
value of 0.05. This implies that there is significant difference in the normalized 
signal contrast ratio between the T2Wfs MRI sequence before and after treatment.  
 
Figure 4.6. Box plot showing the distribution of the normalized mean signal 
intensities from the T2Wfs imaging sequences at time point E1 and E2. T2Wfs 
imaging technique before treatment has a higher contrast ratio than after treatment. 
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Table 4.11 A descriptive statistic at time point E1and E2 shows that after treatment 
the normalized mean signal intensity is less than before. 
 
Table 4.12 Wilcoxon Signed Ranks Test; there is no statistically significant 
difference between E2T2fs↔E1T2fs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Descriptive Statistics 
 N Minimum Maximum Mean Std. Deviation 
E1T2fs 17 .35 5.03 2.7967 1.48836 
E2T2fs 15 -.49 3.98 1.8677 1.38519 
                   Wilcoxon Signed Ranks Test        
Sequences E2T2fs↔E1T2fs 
p value 0.006 
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5. DISCUSSION  
This thesis is part of a big research project work which deals about lymphoma 
cancer study with different imaging modalities, including ultrasound, CT, PET/CT 
and MRI. The objective of this preliminary study is to compare the relative 
conspicuousness of the most common and aggressive NHL, DLBCL on MRI images 
acquired using pre and post contrast enhanced T1-weighted, T2-weighted with and 
without fat suppression MRI protocols and to analyze the changes between the MRI 
sequences before and after one week treatment to chemotherapy. 
Because of its higher sensitivity towards soft tissues, including neoplasm, MRI 
imaging is rapidly becoming one of the preferred imaging modalities. In spite of 
this, there is no clearly defined agreement that states which MRI sequence is best for 
a specific purpose. Improving the sensitivity of MRI for the detection of aggressive 
lymphomas, DLBCL, is vital in the diagnostic workup, staging and treatment 
planning. It is also useful for the better understanding of treatment outcomes in the 
disease follow-up process.  
In this study before and after treatment, the sensitivity of the four MRI sequence 
was quantitatively evaluated based on the normalized mean signal intensity 
calculated from the measured signal intensities of the lesion and normal tissues. In 
addition, this study attempts to see which MRI sequence is better in analyzing the 
response to chemotherapy in patients with diffuse large B-cell lymphoma. 
Conclusion was made based on the statistical analyses.   
5.1. Comparison between sequences before treatment  
The fat suppression MRI sequences are contrast generating sequences that are used 
to suppress the high signal intensity from fat. This can be achieved by enhancing the 
signal generated from water containing tissues and nulling the signal from the fat. 
This is important as most of lesions have high water content. Especially in regions 
where there is high fat content the fat suppression technique result in the reduction 
of background signal intensity from the fat and thus the signal from the  high water 
containing lesion will have a high contrast in the dark background and become more 
conspicuous. Nulling the high signal intensity from the fat will also expand the 
dynamic range of the image display and enhance the tissue contrast (63).  In MRI 
imaging the signal to noise ratio, SNR, can be improved by decreasing the sampling 
bandwidth. Though decreasing the bandwidth increases the SNR, it also produces 
artifacts due to the misplacement of the fat relative to the water. Hence, this increase 
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in artifact can be eliminated by suppressing the signal from fat which results in 
overall increase in the image quality from the fat suppression technique (63).   
The box plot in the figure 4.1 shows that the T2W fat suppression MRI protocol 
has the highest normalized mean signal intensity distribution than the rest of the 
sequences. The descriptive statistics on table 4.1 also clearly shows the mean signal 
value of each sequence at time point E1 and T2Wfs MRI sequence has the highest 
normalized mean signal value.  This implies that the conspicuity level of the lesions 
at time point E1 on T2Wfs MRI sequence is much higher than the rest of the 
sequences. This is supported by the result on the table 4.2 which shows that the 
mean signal intensity difference between the fat suppression sequence and the rest 
of the sequences is in a significant level.  
Previous studies [60, 62] have also shown that the fat suppression MRI 
sequences are more sensitive than the conventional spin echo MRI techniques in 
detecting malignancy, including NHL, of the bone marrow, chest, liver and pelvis 
before treatment. The result also agrees with the other study [64] which compares 
the fat suppression MRI sequence with the spin-echo sequence in detecting 
suspected extreme tumour.The finding of this thesis also agrees with the study on 98 
patients with malignant lymphoma of the bone marrow where the fat suppression 
techniques give a better result in the detection of lymphomatous bone marrow 
involvement and in the disease staging process than the T1W spin echo sequence 
[57].  
5.2. Comparison between sequences after treatment 
After treatment, at time point E2, the box plot in figure 4.2 shows that the T2W fat 
suppression MRI protocol still has the highest normalized mean signal intensity 
distribution than the rest of the sequences. The descriptive statistics on table 4.3 also 
clearly shows the mean signal value of each sequence at time point E2 and T2Wfs 
MRI sequence has the highest mean signal intensity value. This implies that the 
conspicuity level of the lesions after treatment on T2Wfs MRI sequence is still much 
higher than the rest of the sequences. Moreover this difference between the fat 
suppression and other sequence after one week treatment is still in significant level.  
This finding is in agreement with the study on patients with malignant 
lymphoma of the bone marrow who are under evaluation of bone marrow transplant 
after treatment [57]. In this study the fat suppression MRI sequence is compared 
with the T1W spin echo sequence for their ability to detect marrow lymphomas and 
the fat suppression MRI sequence is found to be more superior and also improves 
the discrimination of marrow sclerosis from tumor. 
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5.3. Comparison of sequences between time points E1 and E2 
Comparison between T1W MRI sequences before contrast administration between 
the time points E1 and E2 
The T1 property of a tissue is related to the way how energy is transferred to or 
absorbed from the surrounding medium of the spinning proton. An efficient transfer 
of energy results in short T1 relaxation time. The energy transfer in water molecule 
is not efficient and hence has long T1 relaxation time. Tissues with long T1 
relaxation time will have a lower intensity on the T1W MR image. As tissues that 
are involved in pathological process often have higher water content than in the 
normal ones and hence will have lower signal intensity on the T1W MR image.  
During the course of lymphoma treatment the signal intensity of the MR image 
changes. This is due to the fact that before treatment an active and untreated tumor 
contains high amount of free water and will have a long T1 relaxation time which 
decrease the relative signal intensity of the tumor on the T1W MR image. After 
treatment the amount of free water content in the tumor will reduce and be replaced 
with collagen and fibrotic mass [73]. Hence, T1 relaxation time will not be solely be 
because of the water but also the fibrotic mass too. This results in shortening of the 
T1 relaxation time than before the treatment and at the same time in increase in the 
relative signal intensity on the T1W MR image.    
The box plot in figure 4.3 shows an increment in the mean normalized signal 
intensity distributions after treatment, E2. The descriptive statistics, mean value, on 
table 4.5 also clearly shows the mean signal value of each sequence before and after 
treatment. In this study the relative signal intensity has shown increment after one 
week of treatment cycle. The result on the table 4.6 also shows that there is a 
significant difference in the mean contrast ratio between the time point E1 and E2. 
This implies that the treatment has resulted a significant difference after one week.  
This result is supported by the previous studies on early treatment response 
evaluation in patients with diffuse large B-cell lymphoma [16]. On this previous 
study, the same patients with DLBCL who underwent a standard chemotherapy 
treatment shows a rapid decrease of both tumor metabolic activity and volume as 
early as one week after treatment and this was also compared with the PET/CT and 
provides similar result.   
 
 
 
 
42 
 
 
  
Comparison between T1W MRI sequences after contrast administration  
Clinically, in order to increase the contrast between pathological and normal tissues, 
contrast enhancement agents are introduced which selectively affect the tissue 
relaxation times. The Gd-DPTA, a paramagnetic and gadolinium based substance, is 
one of the commonly used contrast enhancing agents. It has the effect of shortening 
T1 relaxation time in tissues where it accumulates and post contrast T1W image of 
the tissue will have enhanced signal intensity. In this study Gd-DPTA enhancing is 
used as a contrast agent before and after treatment. During the treatment cycle the 
property of the tumour undergoes a change which can be reflected on the MRI 
images.  
From the box plot in figure 4.4, it can be seen that the signal intensity 
distribution has shown a slight increment after treatment. This is clearly seen in 
table 4.7 where the mean signal at E2T1C is a bit higher than at E1T1C.  The mean 
of the change in the mean signal intensity of the pre and post-contrast MR images 
before and after treatment is calculated from table 4.1 and 4.3; that is the level of 
enhancement before the treatment and after treatment; and the absolute change in 
signal intensity in the pre and post-contrast images at time point E1 and E2 is found 
to be 8.09 and 5.20 respectively. This result indicates that the enhancement is less 
after treatment and this implies that there is a decrease in the tumor activity after one 
week of the treatment cycle.  Even if there is a change in the tumor activity before 
and after treatment, this difference is not noticeable in the on the E2T1C. This can be 
seen on table 4.8 which shows that there is no as such significant difference in signal 
contrast ratio between the E2T1C and E1T1C. This is may be due to a short period of 
treatment follow up, one week. This result agrees with a study [75], on mediastinal 
masses in Hodgkin’s lymphoma patients, which state that the diagnostic accuracy of 
the MRI based on the intensity enhancement is efficient if it is after 6 months of 
treatment. The result agrees with a study [77] on mediastinal lymphoma which 
evaluate the quantitative changes in gadolinium enhancement at MRI imaging after 
treatment and finds that gadolinium enhancement of the lymphomatous mass has 
shown a decrease after long term follow up of treatment. This implies that Contrast 
enhancing method can shows the treatment response of patients to chemotherapy if 
it is performed after longer treatment follow up. The cost of the contrast agent, the 
scanning time and the need to acquire the pre contrast T1 for comparison are some 
of the limitations of contrast enhanced MRI method and make the method be 
reserved for cases in which the findings may influence patient management. 
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Comparison between T2W MRI sequences without fat suppression   
The T1W MRI images are better in depicting the anatomy of tissues and post 
contrast T1W can also be used in delineating pathologic tissues. In spite of this, T2W 
MRI images are better than the respective T1W images in depicting pathologies as 
most pathologic tissues contain high amount of water than normal tissues and this 
causes the pathologic tissue to appear more bright than the surrounding tissues [50, 
52,55]. Before treatment an active tumor has a characteristic of large water content 
in the cellular compartment than after treatment. When the proportion of water 
content reduces after treatment the signal intensity of the tissue on T2W image will 
also reduce [77].  
In this study the signal intensity has decreased after treatment which is shown in 
the box plot figure 4.5. The descriptive statistics, mean value, on table 4.9 also 
clearly shows that the mean signal value of T2W after treatment is lower than before 
treatment. Even though there is a decrement in the signal intensity of the T2W MRI 
sequence after treatment, the change was not significant as can be seen on table 
4.10. As described earlier this could be due to the shorter follow up of the treatment, 
one week. This result is in agreement with a previous study [77] on the finding of 
MR changes after treatment on patients with mediastinal lymphoma and the mean 
signal intensity on the T2W has shown a decrease after a longer follow up of 
treatment. Another study [66] on lymphoma of bone marrow has finding that the 
signal intensity has increase in T2W after treatment and this may be due to the type 
of treatment the patient had, radiotherapy, is different than the treatment the patient 
had in this study, chemotherapy.  
 
Comparison between T2W MRI sequences with fat suppression   
As it is described in the previous results the fat suppression MRI protocols give the 
highest contrast ratio hence lesion detectability. Because of the reason described 
above the treatment will have an effect in lowering signal intensity on the T2Wfs 
MR images which is clearly seen on the box plot at figure 4.6 and on table 4.11.  At 
the same time these changes before and after treatment were in a significant level as 
shown in table 4.12. This means that even in a short treatment period the response to 
treatment is clearly seen on the T2Wfs MRI and this is beneficial in the treatment 
response evaluation of patients and follow up to treatment. 
Previous study on the same patients with DLBCL has shown that after one week 
chemotherapy treatment there is a rapid decrease of both tumor metabolic activity 
and volume which is also compared with the PET/CT and provide similar result. 
This implies that the T2W MRI sequence can also provide significant information to 
treatment response evaluation. This finding is in agreement with the study [61] on 
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the magnetic resonance imaging of the bone marrow in hematologic malignancies 
which states that the signal intensity of the marrow on the fat suppression MR 
images gradually decreases after treatment.  
 
5.4. Reliability of the results 
The data’s that are used for the analysis were carefully collected as the right 
slice location and tumor regions is cross checked with diffusion weighted imaging, 
ADC maps and also with the 3D reconstructed images of the corresponding 2D 
images. 
The choices of the statistical analysis method were also taking into consideration 
of the number of patients. As the number of patients were small a non-parametric 
statistical analysis methods were implemented.  
The conclusions were made based on the quantitative data which are more 
powerful than qualitative data’s.  
The same size of region of interest cannot be taken in the entire patient as lesion 
especially which are located in the neck regions were small as compared to 
abdomen or thorax. In addition the conclusion would be stronger if there were visual 
assessment. 
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6. CONCLUSIONS  
The key finding of this study is that the T2-weighted with fat suppression sequence is 
best in detecting lymphoma lesions and evaluating treatment efficacy in patients with 
DLBCL. This is important because patients are not suppose to go through all the MRI 
sequences which are so expensive and time taking, in conditions where contrast 
enhancement is needed. Further clinical studies with large number of patients should be 
performed to determine the sensitivity and specificity of this technique.  
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